Adalimumab

Red

Brand Name(s):Humira
AMGEVITA
Hyrimoz
Imraldi

Indication:Crohn’s disease and Ulcerative colitis (Moderate to severe)

Rationale:1,2,3,8

Considered:May-07

Review Date:Nov-23

Comments:
MHRA -Drug Safety Update
Tumour necrosis factor alpha inhibitors: risk of tuberculosis further information at:
http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON404195
April 14
…………………………
Adalimumab is recommended as a treatment option for adults with plaque psoriasis for whom anti-tumour necrosis factor (TNF) treatment is being considered and when the following criteria are both met.
* The disease is severe as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10.
* The psoriasis has not responded to standard systemic therapies including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation); or the person is intolerant of, or has a contraindication to, these treatments.

Adalimumab should be discontinued in people whose psoriasis has not responded adequately at 16 weeks.

NICE TA146
Adalimumab for the treatment of psoriasis
June 2008